Hostname: page-component-77c89778f8-gvh9x Total loading time: 0 Render date: 2024-07-17T08:16:37.308Z Has data issue: false hasContentIssue false

Focusing on optimality for the translation of precision medicine

Published online by Cambridge University Press:  04 August 2022

Anna R. Kahkoska*
Affiliation:
Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Kristen Hassmiller Lich
Affiliation:
Department of Health Policy and Management, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Michael R. Kosorok
Affiliation:
Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA Department of Statistics and Operations Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
*
Address for correspondence: A. Kahkoska, MD, PhD, 2205A McGavran Greenberg Hall, Chapel Hill, NC 27599, USA. Email: anna_kahkoska@med.unc.edu
Rights & Permissions [Opens in a new window]

Abstract

Type
Perspective
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of The Association for Clinical and Translational Science

The scientific field of precision medicine aims to generate evidence to deliver the right treatment to the right patient at the right time, relying on individual-level data and statistical modeling methods to offer insights into more precise risk stratification, prediction, and treatment recommendations [Reference Kosorok and Laber1Reference Collins and Varmus3]. Early success stories have sparked excitement [Reference Lindsell, Stead and Johnson4Reference Ginsburg and Phillips6]. Fueled by growing momentum, the assumption that precision confers optimality has become so implicit in conversations surrounding precision medicine that it is typically not made explicit – the promise of optimization is just assumed to be part of how precision recommendations are made. Often, this assumption is upheld, and “precision medicine” solutions to clinical challenges do confer improvements over their “one-size-fits-all” counterparts. The utility of precision medicine is particularly evident in heterogeneous populations [Reference Kosorok and Laber1], and the quality of insights will likely only increase as richer data from -omics, electronic health records, wearables, and environmental databases are incorporated into precision medicine models of complex disease processes and treatment mechanisms [Reference Ginsburg and Phillips6,Reference Velmovitsky, Bevilacqua, Alencar, Cowan and Morita7].

Yet, while entangled, precision and optimality are fundamentally different. In the context of precision medicine, to be precise is to be specific or “tailored” to an individual patient, or a subgroup of patients, rather than reflective of an entire population. To be optimal is to be most favorable or desirable. While multiple approaches to statistical modeling or clinical care may increase precision, optimality implies an underlying and direct comparison to establish the best result obtainable, under specific conditions, to maximize or minimize one or more specific outcomes.

The concept of optimality, or the task of optimization, can be found across many disciplines, including those in science, mathematics, and engineering; it is also ubiquitous in business, finance, and policy, among other areas [Reference Kochenderfer and Wheeler8,Reference Ragsdale9]. Many pared-down optimization problems share several key features: objectives (i.e., what should be maximized or minimized), decision variables (i.e., what can be modified to achieve optimization), and constraints (i.e., limits to define what is and is not feasible) [Reference Ragsdale9]. Our goal herein is not to provide an exhaustive review of these definitions. Instead, we aim to formally introduce the need for “recentering” the concept of optimality within precision medicine, illuminating where and why an explicit focus on optimality is needed to augment the existing emphasis on precision. Our thesis is that precision without intentional and sufficiently broad optimality is, in short, doomed to fail when it comes to translating precision medicine to patient care.

To date, the field of precision medicine has generated tremendous insights into mechanisms and models of individualized disease processes and treatment responses via both existing and new data sources, laboratory techniques, and analytic approaches. Yet, as the field advances, mechanisms and models will need to be translated to tools and interventions. Though they are entirely sufficient for individual steps of the discovery pipeline, it is likely that existing indices of clinical effects and statistical rigor construct a view of optimality that will not sustain precision medicine as a treatment paradigm.

Consider a hypothetical scenario in which there is a new treatment for a common disease. Compared to the standard of care, and among a subset of patients, the treatment confers a greater clinical benefit, but it is also more expensive and associated with a different profile of off-target effects; this is a promising setup for precision medicine analytics to guide the delivery of the new treatment to the patients who may benefit, ideally as part of routine clinical care. Though there may be multiple scientific approaches that shed insight on heterogeneity in patient characteristics, treatment responses, and side effects, those which lack rigorous data on biomarker–treatment interactions may be illuminating in the discovery pipeline, but not actionable, thus offering no clear path to optimizing patient outcomes. Alternatively, even if new evidence is actionable, approaches that focus on clinical benefits but ignore costs to patient or providers may be non-starters in real, complex, care settings; introducing precision within routine care often carries a cost (e.g., tool development, patient and provider education, time, resources, etc.) [Reference Chambers, Feero and Khoury2,Reference DeMerle, Kennedy and Palmer10], and failure to consider what is optimal for the spectrum of stakeholders including providers and healthcare systems, and feasible given system constraints and limited resources, may limit the potential impact of an intervention due to implementation and dissemination challenges. Finally, and most importantly, a movement toward precision medicine that fails to consider what is optimal for populations carries a grave risk to propagate and augment the effects of structural racism and other health inequities, particularly with regard to the social determinants of health, access to care, and the affordability of individualized regimens [Reference Bayer and Galea11,Reference Joyner and Paneth12].

A further challenge is rooted in the fact that actionable precision medicine science will be translated to patient care not as one treatment or intervention but rather as a suite of treatments or interventions. Put otherwise, precision medicine– as a treatment paradigm– offers an overarching framework for care delivery that selects one intervention, from multiple possible interventions, to account for individual or subgroup variability in genetic, phenotypic, lifestyle, and environmental factors that may impact the effectiveness of selected interventions. Both development and evaluation of precision medicine in care thus requires a wider view to reflect the complexity matching multiple potential interventions to individual patients, capturing short- and long-term impacts at the patient, provider, healthcare-system, and population levels. In sum, optimality, in precision medicine, is multifaceted, dynamically complex, and context specific; these features are outlined in Table 1.

Table 1. Features of optimality for precision medicine as a treatment paradigm

Despite the daunting nature, defining the intersection of precision and optimality is critical for the later stages of translating precision medicine science into practice [Reference Lindsell, Stead and Johnson4,Reference Woolf13]. The precision framework introduces a degree of complexity at the systems level, but the counterbalance of optimality may help to identify and prioritize opportunities where precision approaches are simple yet effective, including those which rely on clinically accessible data for tailoring and can be operationalized as simple, parsimonious decision rules. Further, an unrelenting focus on precision at the level of individual differences and effects, taken out of context from routine care systems and their constraints, may fail to recognize subpopulations for whom tailoring yields clear benefits that outweigh the costs and resources needed for tailoring. Refocusing optimality alongside precision with a wider angle view may help to inform whether, when, and how to increase precision while balancing limited resources, enhancing translation to practice by generating strategies to yield a global value that exceeds the costs of local implementation. Finally, with a proper framework to evaluate the tradeoffs between the health of populations and the health of individuals, there lies a path for the ultimate translation of precision medicine to communities: improved population outcomes conferred by many smaller, individual-level improvements [Reference Kosorok and Laber1].

We propose that several existing scientific methodologies can help to illuminate aspects of optimality in the context of precision medicine as a treatment paradigm. Implementation science houses theories to understand barriers and facilitators to changing practice, as well as scientific methods to promote and optimize precision medicine interventions given the unique constraints and priorities of different, local healthcare and community settings [Reference Chambers, Feero and Khoury2]. The field of systems science complements implementation science methods by offering further, complexity-aware approaches for optimizing of precision medicine in real-world systems in which new models of care will be deployed and sustained [Reference Meadows14Reference Naumann, Kuhlberg and Sandt17]. Common techniques include mapping stakeholders’ understanding of system structure, patient experiences, and health services (e.g., system dynamics or process flow diagraming) and simulation modeling to support decision making surrounding the delivery of interventions (e.g., cost-effectiveness modeling, agent-based modeling, and discrete event simulation modeling/queueing) [Reference Apostolopoulos, Lich and Lemke18]. Finally, advancements in biostatistics have yielded machine learning-based methods to directly estimate optimal interventions for individual patients, picked from a set of potential interventions, to improve one outcome or set of outcomes, based on an individual’s demographics, clinical status, or response to past treatment(s)[Reference Kosorok and Laber1]. Critically, these algorithms can also be used to optimize the effect of treatments or treatment sequences on long-term rather than proximal outcomes [Reference Kosorok and Laber1]. There is also a growing focus on developing simple and interpretable artificial intelligence algorithms for precision medicine [Reference Zhang, Laber, Tsiatis and Davidian19] and evaluating how different sets of biomarkers can be combined to yield optimized treatment recommendations, yielding new opportunities to refine algorithms for different settings where variable patient data may be readily available [Reference Kang, Janes and Huang20,Reference Laber, Tsiatis, Davidian and Holloway21].

At the same time, optimality is an inherently humanistic concept; particularly when the optimization problem involves clinical medicine and broader health promotion. Learning what is optimal for precision medicine will require a careful mix of objective and subjective appraisal, as well as the reconciliation of the different ideas, values, and constraints across different stakeholders of care delivery and population health. Despite the call for development of interdisciplinary team-based initiatives [Reference Chambers, Feero and Khoury2,Reference Pearson, Califf and Roper22], guidance on the assembly of such cross-disciplinary teams is lacking. The need for multifaceted, dynamically complex, and context-specific evaluation could provide the framework to guide inclusion of the right stakeholders at the right time to achieve effective and equitable translation.

In many ways, the need to re-center optimality alongside precision reflects the readiness of the scientific field to make larger translational steps than before. The research questions have matured from “proof-of-concept” (i.e., how to characterize heterogeneity in phenotypes, prognosis, and treatment responses) to those focused on how to leverage those insights as part of a more precise model of healthcare delivery that balances potential improvements in individual-level outcomes (e.g., clinical metrics and patient preferences) with the outcomes that are important to other stakeholders, the reality of clinical workflows and limited system resources, a need for cost-effectiveness, and an accountability to improving health equity and population health. Fundamental questions that must be addressed for effective translation of the growing evidence from precision medicine science: What is optimal, from whose perspective, over what time frame, and in what setting? Making explicit where the union of precision and optimality lies, for whom and in what context, is critical to driving precision medicine’s long-awaited translation to clinical and community practice.

Acknowledgments

ARK is supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant KL2TR002490. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Disclosures

The authors have no conflicts of interest to declare.

References

Kosorok, MR, Laber, EB. Precision medicine. Annual Review of Statistics and Its Application 2019; 6(1): 263286.CrossRefGoogle ScholarPubMed
Chambers, DA, Feero, WG, Khoury, MJ. Convergence of implementation science, precision medicine, and the learning health care system: a new model for biomedical research. JAMA 2016; 315(18): 1941.Google ScholarPubMed
Collins, FS, Varmus, H. A new initiative on precision medicine. New England Journal of Medicine 2015; 372(9): 793795.Google ScholarPubMed
Lindsell, CJ, Stead, WW, Johnson, KB. Action-informed artificial intelligence—matching the algorithm to the problem. JAMA 2020; 323(21): 21412142.Google ScholarPubMed
Hulsen, T, Jamuar, SS, Moody, AR, et al. From big data to precision medicine. Frontiers in Medicine 2019; 6: 34.Google ScholarPubMed
Ginsburg, GS, Phillips, KA. Precision medicine: from science to value. Health Affairs 2018; 37(5): 694701.Google Scholar
Velmovitsky, PE, Bevilacqua, T, Alencar, P, Cowan, D, Morita, PP. Convergence of precision medicine and public health into precision public health: toward a big data perspective. Frontiers in Public Health 2021; 9: 9.Google Scholar
Kochenderfer, MJ, Wheeler, TA. Algorithms for Optimization. MIT Press, 2019.Google Scholar
Ragsdale, C. Spreadsheet Modeling and Decision Analysis: A Practical Introduction to Business Analytics. Cengage Learning, 2021.Google Scholar
DeMerle, KM, Kennedy, JN, Palmer, OMP, et al. Feasibility of embedding a scalable, virtually enabled biorepository in the electronic health record for precision medicine. JAMA Network Open 2021; 4(2): e2037739e.Google ScholarPubMed
Bayer, R, Galea, S. Public health in the precision-medicine era. New England Journal of Medicine 2015; 373(6): 499501.Google ScholarPubMed
Joyner, MJ, Paneth, N. Seven questions for personalized medicine. JAMA 2015; 314(10): 9991000.Google ScholarPubMed
Woolf, SH. The meaning of translational research and why it matters. JAMA 2008; 299(2): 211213.Google ScholarPubMed
Meadows, DH. Thinking in Systems: A Primer. Chelsea Green Publishing, 2008.Google Scholar
Sterman, JD. Learning from evidence in a complex world. American Journal of Public Health 2006; 96(3): 505514.CrossRefGoogle Scholar
Bayer, S. Review of business dynamics: systems thinking and modeling for a complex world, by J. Sterman. Interfaces 2004; 34(4): 324326.Google Scholar
Naumann, RB, Kuhlberg, J, Sandt, L, et al. Integrating complex systems science into road safety research and practice, part 1: review of formative concepts. Injury Prevention 2020; 26(2): 177183.CrossRefGoogle ScholarPubMed
Apostolopoulos, Y, Lich, KH, Lemke, MK. Complex Systems and Population Health: A Primer. Oxford University Press, 2019.Google Scholar
Zhang, Y, Laber, EB, Tsiatis, A, Davidian, M. Using decision lists to construct interpretable and parsimonious treatment regimes. Biometrics 2015; 71(4): 895904.Google ScholarPubMed
Kang, C, Janes, H, Huang, Y. Combining biomarkers to optimize patient treatment recommendations. Biometrics 2014; 70(3): 695707.Google ScholarPubMed
Laber, EB, Tsiatis, AA, Davidian, M, Holloway, ST. Discussion of “Combining biomarkers to optimize patient treatment recommendation.” Biometrics 2014; 70(3): 707.Google ScholarPubMed
Pearson, TA, Califf, RM, Roper, R, et al. Precision health analytics with predictive analytics and implementation research: JACC State-of-the-Art review. Journal of the American College of Cardiology 2020; 76(3): 306320.Google ScholarPubMed
Homer, JB, Hirsch, GB. System dynamics modeling for public health: background and opportunities. American Journal of Public Health 2006; 96(3): 452458.CrossRefGoogle ScholarPubMed
Luke, DA, Stamatakis, KA. Systems science methods in public health: dynamics, networks, and agents. Annual Review of Public Health 2012; 33(1): 357376.CrossRefGoogle ScholarPubMed
Figure 0

Table 1. Features of optimality for precision medicine as a treatment paradigm